| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df493aec811c46b53ab16f0e1a115b8a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-559
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0602 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2011-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe9aba4a587f36ef3c9c932b95968b09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3be26fe34c06afaa2506ae76f76afe88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e224da7a8ff33a46f887c793ed4ef04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f77c1dda8fc8d000aafc1666944c4579 |
| publicationDate |
2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2862955-T3 |
| titleOfInvention |
Manipulated nucleic acids and methods of using them |
| abstract |
A kit for the administration of two mRNA constructs modified in vivo to cause intracellular translation of the mRNA constructs into heavy and light chains of an immunoglobulin protein, the kit comprising a first isolated nucleic acid that is translatable mRNA that i) encodes a immunoglobulin heavy chain or an immunoglobulin light chain and ii) comprises a modified nucleoside; wherein the first nucleic acid is capable of evading an innate immune response from a cell into which the isolated first nucleic acid is introduced, wherein the translatable mRNA is devoid of cytidine or uracil nucleotides. |
| priorityDate |
2010-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |